Engineering of <sup>177</sup>Lu-labeled gold encapsulated into dendrimeric nanomaterials for the treatment of lung cancer

Wang, Zheng; Ye, Minhua; Ma, Dehua; Shen, Jianfei; Fang, Fang

doi:10.1080/09205063.2021.1982446

Cited by 11 publications

(12 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wang et al. suggested that GRPR might be a helpful specific target for therapy if combined with folate-bombesin ( 79 ). However, few studies had investigated the GRPR targeting potential in human head and neck squamous cell carcinoma.…”

Section: Discussionmentioning

confidence: 99%

pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy

Gao

Zhao

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC) is the most common type of cancer occurring in the oral and maxillofacial regions. Despite of the advances in the diagnosis and treatment, the overall 5-year survival rate has remained about 40%–50% in the past decades. Various nanotechnology-based carrier systems have been investigated for their potentials in the OSCC treatment. However, because of the lack of active targeting of tumors, their application is limited. Studies have shown that gastrin-releasing peptide receptors (GRPRs) are overexpressed on many human cancers, including head and neck squamous cell carcinoma. Herein, we aimed to develop a GRPR-targeted nano-graphene oxide (NGO) nanoprobe drug delivery system for OSCC therapy. DOX@NGO-BBN-AF750 was synthesized by the non-covalent bonding method to couple carboxylated NGO with BBN-AF750 (bombesin antagonist peptides conjugated to Alexa Fluor 750) and DOX (doxorubicin) through π-π and hydrogen bonding. Internalization and antitumor activities were carried out in human HSC-3 cancer cells. The tumor pH microenvironment was simulated to study the release of antitumor drug DOX from the DOX@NGO-ant BBN-AF750 complex under different pH conditions. DOX@NGO-BBN-AF750 showed internalization into HSC-3 cells. The IC50 (50% inhibitory concentration) was 5 µg/ml for DOX@NGO-BBN-AF750 in HSC-3 cells. Furthermore, DOX@NGO-BBN-AF750 showed a pH-sensitive drug release rate, and a dose-dependent and pH-responsive cytotoxicity in HSC-3 cells. DOX@NGO-BBN-AF750 presents the characteristics ensuring a slow release of DOX from the nanoprobe, thereby protecting the drug from degradation and prolonging the half-life of the drug. This report provides a versatile strategy to achieving targeted and imaging-guided therapy of OSCC.

show abstract

Section: Discussionmentioning

confidence: 99%

pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy

Gao

Zhao

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…RGD sequence against integrin αυβ3 [29,30], prostate-specific membrane antigen (PSMA) inhibiting peptides for targeting of prostate cancer) or cellular penetration (e.g., Tat (49)(50)(51)(52)(53)(54)(55)(56)(57), HIV-1 derived sequence [31,32]).…”

Section: Of 38mentioning

confidence: 99%

“…Nevertheless, with no carboxylic groups available on the surface of the nanoparticle, nanoparticle's surface, or no amine group available in the ligand, the other way around can be equally efficient [16,47]. Poly(amidoamine) (PAMAM) dendrimers were conjugated with DOTA-modified BBN using the amine group on the dendrimer and carboxylic group of the DOTA moiety [48,49]. Hajiramezanali and co-workers used this approach to exploit amine groups on chitosan and conjugate succinylated BBN derivative [50].…”

Section: Accardo Et Al Analyzed the Performance Of Seven Different Gr...mentioning

confidence: 99%

“…Hajiramezanali and co-workers used this approach to exploit amine groups on chitosan and conjugate succinylated BBN derivative [50]. However, organic solvents and water-insoluble substrates are also used, such as 2-(1H-7-azabenzotriazol-1-yl)-1.1.3.3-tetramethyluroniumhexafluorophosphate) (HATU) [49,51,52] or N,N′-dicyclohexyl carbodiimide (DCC) [38,53] in DMF with the addition of N,N-diisopropylethylamine (DIPEA) [49]. Also, click chemistry such as thiol-maleimide [36,54,55] or copper-catalyzed azide-alkyne cycloaddition was useful [43,44,56,57].…”

Section: Accardo Et Al Analyzed the Performance Of Seven Different Gr...mentioning

confidence: 99%

See 1 more Smart Citation

Nanostrategies for Therapeutic and Diagnostic Targeting of Gastrin-Releasing Peptide Receptor

Rurarz¹,

Bukowczyk²,

Gibka³

et al. 2023

Preprint

View full text Add to dashboard Cite

Advances in nanomedicine bring the attention of researchers to the molecular targets which can play a major role in the development of novel therapeutic and diagnostic modalities for cancer management. The choice of a proper molecular target can decide on the efficacy of the treatment and endorse the personalized medicine approach. Gastrin-releasing peptide receptor (GRPR) is a G-protein-coupled membrane receptor, well known to be overexpressed in numerous malignancies including pancreatic, prostate, breast, lung, colon, cervical and gastrointestinal cancers. Therefore, many research groups express a deep interest in targeting GRPR with their nanoformulations. A broad spectrum of the GRPR ligands has been described in the literature, which allows tuning of the properties of the final formulation, particularly in the field of the ligand affinity to the receptor and internalization possibilities. Hereby the recent advances in the field of applications of various nanoplatforms which are able to reach the GRPR expressing cells are reviewed.

show abstract

“…Tumor-suppressive effects are typically higher with radiolabeled 177 Lu-DTPA-pAuNS in combination with photothermal therapy than the individual therapy of 177 Lu-DTPA-pAuNS in head and neck squamous cell carcinoma [ 39 ]. Another study described the efficacy of ‘PAMAM-G4–( 177 Lu–dendrimer)–bombesin–folate’ for targeting gastrin-releasing peptide receptors as well as folate receptors in lung cancer cells [ 40 ]. Hence, 177 Lu-labeled nanosystems could be considered as efficient theranostic radioactive components.…”

Section: Introductionmentioning

confidence: 99%

Novel Implications of Nanoparticle-Enhanced Radiotherapy and Brachytherapy: Z-Effect and Tumor Hypoxia

et al. 2022

View full text Add to dashboard Cite

Radiotherapy and internal radioisotope therapy (brachytherapy) induce tumor cell death through different molecular signaling pathways. However, these therapies in cancer patients are constrained by dose-related adverse effects and local discomfort due to the prolonged exposure to the surrounding tissues. Technological advancements in nanotechnology have resulted in synthesis of high atomic elements such as nanomaterials, which can be used as radiosensitizers due to their photoelectric characteristics. The aim of this review is to elucidate the effects of novel nanomaterials in the field of radiation oncology to ameliorate dose-related toxicity through the application of ideal nanoparticle-based radiosensitizers such as Au (gold), Bi (bismuth), and Lu (Lutetium-177) for enhancing cytotoxic effects of radiotherapy via the high-Z effect. In addition, we discuss the role of nanoparticle-enhanced radiotherapy in alleviating tumor hypoxia through the nanodelivery of genes/drugs and other functional anticancer molecules. The implications of engineered nanoparticles in preclinical and clinical studies still need to be studied in order to explore potential mechanisms for radiosensitization by minimizing tumor hypoxia, operational/logistic complications and by overcoming tumor heterogeneity in radiotherapy/brachytherapy.

show abstract

Engineering of ¹⁷⁷Lu-labeled gold encapsulated into dendrimeric nanomaterials for the treatment of lung cancer

Cited by 11 publications

References 54 publications

pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy

pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy

Nanostrategies for Therapeutic and Diagnostic Targeting of Gastrin-Releasing Peptide Receptor

Novel Implications of Nanoparticle-Enhanced Radiotherapy and Brachytherapy: Z-Effect and Tumor Hypoxia

Contact Info

Product

Resources

About

Engineering of 177Lu-labeled gold encapsulated into dendrimeric nanomaterials for the treatment of lung cancer

Cited by 11 publications

References 54 publications

pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy

pH-responsive graphene oxide loaded with targeted peptide and anticancer drug for OSCC therapy

Nanostrategies for Therapeutic and Diagnostic Targeting of Gastrin-Releasing Peptide Receptor

Novel Implications of Nanoparticle-Enhanced Radiotherapy and Brachytherapy: Z-Effect and Tumor Hypoxia

Contact Info

Product

Resources

About

Engineering of ¹⁷⁷Lu-labeled gold encapsulated into dendrimeric nanomaterials for the treatment of lung cancer